Suppr超能文献

基于Child-Turcotte-Pugh评分的改良抗结核治疗方案用于失代偿期肝硬化合并结核病患者:一项来自印度北部的两年回顾性观察研究

Child-Turcotte-Pugh score-based modified anti-tubercular treatment in patients with decompensated cirrhosis with tuberculosis: A two-year retrospective observational study from North India.

作者信息

Ahmad Juned

机构信息

Myra Liver Gastro and Endoscopy Centre, Chowk, Lucknow, 226 020, India.

出版信息

Indian J Gastroenterol. 2025 Aug 29. doi: 10.1007/s12664-025-01860-x.

Abstract

BACKGROUND

Management of tuberculosis in decompensated cirrhosis is challenging, as the risk of severe liver failure is markedly increased if hepatotoxicity develops secondary to anti-tubercular treatment (ATT). Child-Turcotte-Pugh (CTP) score-based ATT by Dhiman et al. proposed that the number of hepatotoxic drugs should be two, one and none in CTP scores of ≤ 7, 8-10 and ≥ 11, respectively. We present here our retrospective observational study of treating tuberculosis in patients with decompensated cirrhosis utilizing the above-mentioned CTP-based ATT regimens.

METHODS

A retrospective observational study utilizing electronic data search was conducted on the application-based software for the duration from April 2022 to April 2024. On the software, decompensated cirrhosis with tuberculosis patients were already tagged. The modified ATT regimens (weight-based) were as per the CTP score. With CTP score ≥ 11, no hepatotoxic drug was included: Intensive Phase -ELA (Ethambutol, Levofloxacin and Amikacin); Continuation Phase: EL. With CTP scores 8-10, 1 hepatotoxic drug (rifampicin preferred) was included; Intensive Phase: RELA, R Rifampicin; Continuation Phase: REL. CTP score ≤ 7 received two hepatotoxic drugs, Intensive Phase: HREL, H Isoniazid, Continuation Phase: HRE. The duration of ATT's continuation phase was 12-18 months.

RESULTS

Of 155 patients with decompensated cirrhosis, 21 (13.5%) had concomitant tuberculosis. CTP score-based modified ATT was administered to all 21 during the Intensive phase. Drug-induced hepatotoxicity developed in four patients (19.1%) during the intensive phase. After the intensive phase, two patients were lost to follow-up. Out of 19 patients who completed the continuation phase, 15 (78.9%) had a resolution of tuberculosis and four (21.1%) died. The cause for death in all four patients was related to cirrhosis.

CONCLUSION

As per our study, patients with decompensated cirrhosis tolerated the CTP-score-based modified ATT and almost 80% had a resolution of tuberculosis.

摘要

背景

失代偿期肝硬化患者的结核病管理具有挑战性,因为抗结核治疗(ATT)继发肝毒性时,严重肝衰竭的风险会显著增加。Dhiman等人提出的基于Child-Turcotte-Pugh(CTP)评分的ATT方案建议,在CTP评分≤7、8 - 10和≥11时,肝毒性药物的数量应分别为两种、一种和零种。在此,我们展示了我们利用上述基于CTP的ATT方案治疗失代偿期肝硬化患者结核病的回顾性观察研究。

方法

利用电子数据检索进行了一项回顾性观察研究,研究时间为2022年4月至2024年4月,使用基于应用程序的软件。在该软件上,已标记了患有失代偿期肝硬化合并结核病的患者。改良的ATT方案(基于体重)根据CTP评分制定。CTP评分≥11时,不包含肝毒性药物:强化期 - ELA(乙胺丁醇、左氧氟沙星和阿米卡星);持续期:EL。CTP评分为8 - 10时,包含1种肝毒性药物(首选利福平);强化期:RELA,R代表利福平;持续期:REL。CTP评分≤7时使用两种肝毒性药物,强化期:HREL,H代表异烟肼;持续期:HRE。ATT持续期为12 - 18个月。

结果

在155例失代偿期肝硬化患者中,21例(13.5%)合并结核病。在强化期,所有21例患者均接受了基于CTP评分的改良ATT。4例患者(19.1%)在强化期出现药物性肝毒性。强化期后,2例患者失访。在完成持续期的19例患者中,15例(78.9%)结核病得到缓解,4例(21.1%)死亡。所有4例患者的死亡原因均与肝硬化有关。

结论

根据我们的研究,失代偿期肝硬化患者能够耐受基于CTP评分的改良ATT,近80%的患者结核病得到缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验